Loading stock data…
Aclarion (ACON)
$2.85+0.05 (+1.78%)
Market OpenUpdated 1:54 PM EDT
Aclarion, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aclarion, Inc. in the Healthcare sector is trading at $2.85 with a market capitalization of $7M. Wall Street consensus targets $7.50 (1 analysts), implying a +162.7% move over the next 12 months. The stock is currently near its 52-week low of $2.34, remaining 40.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +162.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $21,140↑ | $18,479↓ | $18,942↓ | $19,319↑ | $18,991 |
| Gross Profit | $3,750↑ | $1,791↓ | $4,386↓ | $5,140↑ | -$4,488 |
| Operating Income | -$2.99M↓ | -$1.99M↓ | -$1.83M↓ | -$1.74M↓ | -$1.49M |
| Net Income | -$2.85M↓ | -$1.89M↓ | -$1.71M↓ | -$1.60M↑ | -$2.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.19M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.96%
Volume
Today's trading volume
27,079
Recent News
Aclarion (ACON) Upgraded to Buy: Here's Why
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
Aclarion (ACON) delivered earnings and revenue surprises of +13.55% and -29.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of -5.26% and +13.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aclarion Second Quarter 2025 Earnings: Misses Expectations
Aclarion ( NASDAQ:ACON ) Second Quarter 2025 Results Key Financial Results Net loss: US$1.60m (loss widened by 29% from...